MedicalResearch.com Interview with: [caption id="attachment_66982" align="alignleft" width="150"] Dr. Vodstrcil[/caption] Lenka Vodstrcil PhD Senior Research Fellow Deputy Head, Genital Microbiota and Mycoplasma Group President, Sexual Health Society of Victoria Associate Editor, Sexually Transmitted Infections School of Translational Medicine, FMNHS, Monash University Melbourne Sexual Health Centre, The Alfred Hospital Melbourne School of Population & Global Health, University of Melbourne [caption id="attachment_66983" align="alignleft" width="150"] Dr. Bradshaw[/caption] Catriona Bradshaw MMBS(Hons), PhD, FAChSHM, FAHMS Professor (Research), Head of Research Translation and Mentorship and of The Genital Microbiota and Mycoplasma Group Melbourne School of Translational Medicine, Monash University and Alfred Hospital Principal Research Fellow at the Burnet Institute   MedicalResearch.com: What is the background for this study? Response: One in three women globally have bacterial vaginosis (BV), a condition that causes a malodourous discharge, and associated with serious gynaecologic and obstetric sequelae (including miscarriage and preterm birth) and increases the risk sexually transmitted infections (STIs) and HIV. Women with symptoms are treated with broad-spectrum antibiotics, however, over 50% of women experience BV recurrence within 3-6 months. The recurrence rate is even higher at 60-80% among women with an ongoing regular partner. Current practice is to simply retreat women experiencing BV recurrence with the same antibiotics, which leaves them (and clinicians) frustrated and distressed. We and others have accumulated a body of evidence to show that BV has the profile of an STI. BV-associated bacteria are detected in men in the distal urethra and on penile-skin, and couples share these organisms. However, to date, has not been recommended for BV as it is for other STIs. This is largely because men do not usually have any symptoms, and past partner-treatment trials in the 1980s and 1990s, which only used oral antibiotics for men, failed to prevent BV recurrence, which was taken as conclusive evidence against sexual transmission. Reviews of these trials have since identified their limitations. Given the evidence of male carriage of BV-associated bacteria at two genital sites, we hypothesised that both sites needed to be targeted with antimicrobial therapy to prevent re-infection post-treatment. The aim of our study was to assess if male partner-treatment concurrently with female treatment using a combination of oral and topical antibiotics for the first time, would decrease BV recurrence over 12 weeks compared to the current standard practice of treating women only.